Abstract
The aim of this study is to investigate the association of IκBα promoter polymorphisms with the development of Multiple Sclerosis (MS) disease in Iranian population. One hundred and fifty patients with MS along with 150 unrelated healthy controls were enrolled in this study. The IκBα −881A/G (rs3138053), −826C/T (rs2233406) and −519C/T (rs2233408) polymorphisms were determined by the polymerase chain reaction/restriction fragment length polymorphism method. This study demonstrated that the genotype frequencies of IκBα −881A/G and −826T/T, and allele frequencies of IκBα−881G were significantly higher in patients with MS with respect to as compared to the controls. We also found that the estimated haplotype frequency of IκBα promoter −881G–826T–519C was significantly increased in the patient with MS in comparison with that of the healthy individuals. This study reveals that polymorphisms in the IκBα promoter (−881 A/G, −826 C/T) are strongly associated with the susceptibility of Iranian MS patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Noteworthy J, Lucchinetti C, Rodriguez M, Weinshenker B (2000) Medical progress: multiple sclerosis. New Engl J Med 343:938–952
Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis results of an international survey. Neurology 46:907–911
Ramagopalan SV, Dobson R, Meier UC, Giovannoni G (2010) Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol 9:727
Dyment DA, Ebers GC, Dessa Sadovnick A (2004) Genetics of multiple sclerosis. Lancet Neurol 3:104–110
Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476:214–219
Sospedra M, Martin R (2005) Immunology of multiple sclerosis. Annu Rev Immunol 23:683–747
Liang Y, Zhou Y, Shen P (2004) NF-kappaB and its regulation on the immune system. Cell Mol Immunol 1:343–350
Gveric D, Kaltschmidt C, Cuzner ML, Newcombe J (1998) Transcription factor NF-kappaB and inhibitor I kappaBalpha are localized in macrophages in active multiple sclerosis lesions. J Neuropath Exp Neurol 57:168
Chen F, Castranova V, Shi X, Demers LM (1999) New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45:7–17
Qiutang L, Inder M (2002) NF-KB regulation in the immune system. Immunology 2:725–734
Mozzato-Chamay N, Corbett E, Bailey R, Mabey D, Raynes J, Conway D (2001) Polymorphisms in the IkappaB-alpha promoter region and risk of diseases involving inflammation and fibrosis. Genes Immun 2:153
Ito CY, Kazantsev AG, Baldwin AS Jr (1994) Three NF-χB sites in the IχB-α promoter are required for induction of gene expression by TNFα. Nucleic Acids Res 22:3787–3792
Lin C-H, Wang S-C, Ou T-T, Li R-N, Tsai W-C, Liu H-W, Yen J-H (2008) IκBα promoter polymorphisms in patients with systemic lupus erythematosus. J Clin Immunol 28:207–213
Lin CH, Ou TT, Wu CC, Tsai WC, Liu HW, Yen JH (2007) IκBα promoter polymorphisms in patients with rheumatoid arthritis. Int J Immunogenet 34:51–54
Ou T-T, Lin C-H, Lin Y-C, Li R-N, Tsai W-C, Liu H-W, Yen J-H (2008) IkBα promoter polymorphisms in patients with primary Sjögren’s syndrome. J Clin Immunol 28:440–444
Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-Palumbo A, Gaudio F, Turco MC, Petrella A, Maria R (2005) NF-κB protects Behçet’s disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum 52:2179–2191
Iwai K, Lee BR, Hashiguchi M, Fukushima A, Iwashima M (2005) IkB-α-specific transcript regulation by the C-terminal end of c-Rel. FEBS Lett 579:141–144
Siebenlist U, Franzoso G, Brown K (1994) Structure, regulation and function of NF-kappaB. Annu Rev Cell Biol 10:405–455
Arenzana-Seisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier J-L, Dargemont C (1997) Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 110:369–378
Miterski B, Böhringer S, Klein W, Sindern E, Haupts M, Schimrigk S, Epplen J (2002) Inhibitors in the NFκB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations. Genes Immun 3:211–219
Li R-N, Hung Y-H, Lin C-H, Chen Y-H, Yen J-H (2010) Inhibitor IκBα promoter functional polymorphisms in patients with rheumatoid arthritis. J Clin Immunol 30:676–680
Acknowledgments
This study was supported by Tarbiat Modares University and we thank Dr. Manshadi and Dr. Taghikhani for providing normal samples.
Conflict of interest
No potential conflicts of interest were disclosed.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balood, M., Mesbah-Namin, S.A., Sanati, M.H. et al. Inhibitor IκBα promoter functional polymorphisms in patients with multiple sclerosis. Mol Biol Rep 41, 613–616 (2014). https://doi.org/10.1007/s11033-013-2898-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-013-2898-3